MA34735B1 - Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil - Google Patents

Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil

Info

Publication number
MA34735B1
MA34735B1 MA36010A MA36010A MA34735B1 MA 34735 B1 MA34735 B1 MA 34735B1 MA 36010 A MA36010 A MA 36010A MA 36010 A MA36010 A MA 36010A MA 34735 B1 MA34735 B1 MA 34735B1
Authority
MA
Morocco
Prior art keywords
tenofovir disoproxil
disoproxil fumarate
therapeutic compositions
rilpivirine hydrochloride
hydrochloride
Prior art date
Application number
MA36010A
Other languages
English (en)
Inventor
Reza Oliyai
Lauren Wiser
Mark Menning
Original Assignee
Janssen R & D Ireland
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34735(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland, Gilead Sciences Inc filed Critical Janssen R & D Ireland
Publication of MA34735B1 publication Critical patent/MA34735B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des comprimés multicouches qui contiennent un hydrochlorure de rilpivirine, un emtricitabine et un fumarate de ténofovir disoproxil. Les comprimés sont utilisés pour traiter le VIH.
MA36010A 2010-11-19 2013-06-14 Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil MA34735B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19
PCT/US2011/061515 WO2012068535A1 (fr) 2010-11-19 2011-11-18 Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil

Publications (1)

Publication Number Publication Date
MA34735B1 true MA34735B1 (fr) 2013-12-03

Family

ID=45094284

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36010A MA34735B1 (fr) 2010-11-19 2013-06-14 Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil

Country Status (36)

Country Link
US (1) US10857102B2 (fr)
EP (2) EP2826466A1 (fr)
JP (2) JP2014500261A (fr)
KR (1) KR101923103B1 (fr)
CN (2) CN103491948B (fr)
AP (1) AP3816A (fr)
AR (2) AR084500A1 (fr)
AU (3) AU2011329642B2 (fr)
BR (1) BR112013012245B1 (fr)
CA (1) CA2818097C (fr)
CL (1) CL2013001402A1 (fr)
CO (1) CO6761300A2 (fr)
CR (1) CR20130293A (fr)
DK (1) DK2640362T4 (fr)
EA (2) EA025852B1 (fr)
EC (2) ECSP13012700A (fr)
ES (1) ES2524408T5 (fr)
HK (1) HK1206592A1 (fr)
HR (1) HRP20140946T1 (fr)
IL (1) IL226300B (fr)
MA (1) MA34735B1 (fr)
ME (1) ME01980B (fr)
MX (1) MX347512B (fr)
MY (1) MY185604A (fr)
NZ (1) NZ610729A (fr)
PE (3) PE20170521A1 (fr)
PH (1) PH12013501002A1 (fr)
PL (1) PL2640362T5 (fr)
PT (1) PT2640362E (fr)
RS (1) RS53691B1 (fr)
SG (3) SG10201912527XA (fr)
SM (1) SMT201400150B (fr)
TW (1) TWI556840B (fr)
UA (1) UA114075C2 (fr)
WO (1) WO2012068535A1 (fr)
ZA (1) ZA201304481B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI556840B (zh) 2010-11-19 2016-11-11 吉李德科學股份有限公司 治療用組成物
CN110343135A (zh) 2011-08-16 2019-10-18 吉利德科学公司 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
CA2779052A1 (fr) * 2012-05-31 2013-11-30 Pharmascience Inc. Composition pharmaceutique d'antecavir et processus de fabrication
CA2893843C (fr) 2012-12-21 2018-09-04 Gilead Sciences, Inc. Composes de carbamoylpyridone polycycliques et leur utilisation pharmaceutique
WO2015014737A1 (fr) * 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations pour comprimés multicouches comprenant du tenofovir et de l'entécavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (fr) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Dispersion solide amorphe comprenant du paclitaxel, comprimé la comprenant, et son procédé de préparation
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
CA2921336A1 (fr) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Formulations pharmaceutiques
SI3346995T1 (sl) 2015-11-09 2019-11-29 Gilead Sciences Inc Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
EP3439639A1 (fr) * 2016-04-08 2019-02-13 Shionogi & Co., Ltd. Forme posologique solide stabilisée
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
CN110958883A (zh) * 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
BR112021026916A2 (pt) * 2019-07-03 2022-05-10 Janssen Sciences Ireland Unlimited Co Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (fr) * 2023-04-07 2024-10-10 Navinta, Llc Compositions stables de rilpivirine hcl en combinaison avec d'autres agents anti-retroviraux
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2002359518A1 (en) 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
WO2006024668A1 (fr) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
DK1632232T6 (da) 2004-09-02 2022-04-19 Janssen Pharmaceutica Nv Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CA2625776A1 (fr) 2005-10-14 2007-04-26 Microdose Technologies, Inc. Conditionnement pharmaceutique d'une combinaison posologique orale
US20080317852A1 (en) 2005-12-14 2008-12-25 Amar Lulla Pharmaceutical Combination
EP4403221A3 (fr) * 2007-02-23 2024-10-09 Gilead Sciences, Inc. Modulateurs des propriétés pharmacocinétiques d'agents thérapeutiques
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (fr) 2007-05-16 2008-11-20 Fmc Corporation Forme solide
WO2008143500A1 (fr) 2007-05-22 2008-11-27 Ultimorphix Technologies B.V. Co-cristaux de tenofovir disoproxil acide hémi-fumarique
WO2009037449A1 (fr) 2007-09-18 2009-03-26 Cipla Limited Compositions pharmaceutiques solides comprenant un ou plusieurs inhibiteurs du virus de l'herpès et un ou plusieurs inhibiteurs de la transcriptase inverse
WO2009106960A2 (fr) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Compositions stables de lamivudine, de ténofovir et d'éfavirenz
CN103479584A (zh) 2008-05-02 2014-01-01 吉里德科学公司 固体载体颗粒在改善药物制剂加工性中的应用
CN102307573B (zh) 2009-02-06 2013-09-11 吉里德科学公司 用于联合治疗的片剂
AU2010295373B2 (en) 2009-09-21 2016-09-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011077100A1 (fr) 2009-12-24 2011-06-30 Cipla Limited Composition antirétrovirale
TWI556840B (zh) 2010-11-19 2016-11-11 吉李德科學股份有限公司 治療用組成物

Also Published As

Publication number Publication date
PE20211657A1 (es) 2021-08-24
CL2013001402A1 (es) 2013-12-27
SG190333A1 (en) 2013-06-28
IL226300B (en) 2019-05-30
JP6138851B2 (ja) 2017-05-31
JP2014500261A (ja) 2014-01-09
SG10201912527XA (en) 2020-02-27
BR112013012245A2 (pt) 2016-08-09
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
EP2640362B1 (fr) 2014-09-10
KR101923103B1 (ko) 2018-11-28
TW201238612A (en) 2012-10-01
EA025852B1 (ru) 2017-02-28
ES2524408T5 (es) 2022-04-25
AU2016208417B2 (en) 2018-04-05
AP3816A (en) 2016-09-30
MY185604A (en) 2021-05-25
MX347512B (es) 2017-04-28
HK1190064A1 (en) 2014-06-27
ME01980B (fr) 2015-05-20
BR112013012245B1 (pt) 2022-09-27
UA114075C2 (xx) 2017-04-25
ES2524408T3 (es) 2014-12-09
CR20130293A (es) 2013-10-03
CN103491948B (zh) 2016-11-02
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
CN103491948A (zh) 2014-01-01
AU2011329642A1 (en) 2013-05-02
CO6761300A2 (es) 2013-09-30
AU2018202635A1 (en) 2018-05-10
AR123409A2 (es) 2022-11-30
PL2640362T3 (pl) 2015-03-31
NZ610729A (en) 2015-10-30
PE20170521A1 (es) 2017-05-27
EP2640362B2 (fr) 2021-12-01
SMT201400150B (it) 2015-01-15
EP2640362A1 (fr) 2013-09-25
CA2818097C (fr) 2019-07-30
EA201390651A1 (ru) 2013-11-29
EP2826466A1 (fr) 2015-01-21
HRP20140946T1 (hr) 2015-02-13
HK1206592A1 (en) 2016-01-15
SG10201509521WA (en) 2015-12-30
PH12013501002A1 (en) 2013-09-09
PL2640362T5 (pl) 2022-05-02
DK2640362T3 (en) 2014-12-01
ECSP13012700A (es) 2013-08-30
EA201691695A1 (ru) 2017-11-30
CA2818097A1 (fr) 2012-05-24
PT2640362E (pt) 2014-11-28
MX2013005669A (es) 2013-11-04
RS53691B1 (sr) 2015-04-30
US20130243857A1 (en) 2013-09-19
TWI556840B (zh) 2016-11-11
WO2012068535A1 (fr) 2012-05-24
KR20140037799A (ko) 2014-03-27
AP2013006931A0 (en) 2013-06-30
US10857102B2 (en) 2020-12-08
ZA201304481B (en) 2022-03-30
AR084500A1 (es) 2013-05-22
JP2015131853A (ja) 2015-07-23
PE20140163A1 (es) 2014-02-08
AU2016208417A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
EA201390651A1 (ru) Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
SA519402217B1 (ar) مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون
JOP20190041A1 (ar) مركبات وتركيبات كمثبطات لمستقبلات شبيهة بالتول إندوسومية
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA44890A (fr) Compositions comprenant des souches bactériennes
MA44322A (fr) Compositions comprenant des souches bactériennes
MY191357A (en) Sustained-release dosage forms of ruxolitinib
MA42471A (fr) Compositions comprenant des souches bactériennes
MX2017016802A (es) Formulaciones farmaceuticas.
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA37840A3 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
SMT202400166T1 (it) Analoghi della benzazepina come agenti inibitori della tirosin chinasi di bruton
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EP4424373A3 (fr) Compositions pharmaceutiques contenant de la doravirine, du fumarate de ténofovir disoproxil et de lamivudine
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2017010323A (es) Formulaciones farmaceuticas de inhibidor de esterasa c1.
FR2990843B1 (fr) Dispositif d'attache implantable, implant pour le traitement des prolapsus de la statique pelvienne comportant un tel dispositif et kit comprenant ledit dispositif.
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
CY1116115T1 (el) Θεραπευτικες συνθεσεις οι οποιες αποτελουνται απο ριλπιβιρινη hcl και δισοπροξιλικη φουμαρικη τενοφοβιρη
MA45200A (fr) Compositions comprenant des souches bactériennes